RU2324484C2 - Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) - Google Patents

Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) Download PDF

Info

Publication number
RU2324484C2
RU2324484C2 RU2005101411/15A RU2005101411A RU2324484C2 RU 2324484 C2 RU2324484 C2 RU 2324484C2 RU 2005101411/15 A RU2005101411/15 A RU 2005101411/15A RU 2005101411 A RU2005101411 A RU 2005101411A RU 2324484 C2 RU2324484 C2 RU 2324484C2
Authority
RU
Russia
Prior art keywords
glutamate receptor
metabotropic glutamate
gastroesophageal reflux
treatment
antagonist
Prior art date
Application number
RU2005101411/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2005101411A (ru
Inventor
Андерс ЛЕХМАН (SE)
Андерс ЛЕХМАН
Ян МАТСОН (SE)
Ян МАТСОН
Томас М. СТОРМЭН (US)
Томас М. СТОРМЭН
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2324484(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2005101411A publication Critical patent/RU2005101411A/ru
Application granted granted Critical
Publication of RU2324484C2 publication Critical patent/RU2324484C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2005101411/15A 2002-06-20 2003-06-19 Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) RU2324484C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use
SE0201943-8 2002-06-20

Publications (2)

Publication Number Publication Date
RU2005101411A RU2005101411A (ru) 2005-07-10
RU2324484C2 true RU2324484C2 (ru) 2008-05-20

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005101411/15A RU2324484C2 (ru) 2002-06-20 2003-06-19 Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)

Country Status (24)

Country Link
EP (1) EP1513525B1 (enExample)
JP (2) JP4683920B2 (enExample)
CN (1) CN100430056C (enExample)
AT (1) ATE395059T1 (enExample)
AU (1) AU2003241585B2 (enExample)
BR (1) BR0311759A (enExample)
CA (1) CA2489730C (enExample)
CY (1) CY1107954T1 (enExample)
DE (1) DE60320990D1 (enExample)
DK (1) DK1513525T3 (enExample)
ES (1) ES2304510T3 (enExample)
IL (1) IL165138A0 (enExample)
IS (1) IS7654A (enExample)
MX (1) MXPA04012659A (enExample)
NO (1) NO20050154L (enExample)
NZ (1) NZ536559A (enExample)
PL (1) PL372186A1 (enExample)
PT (1) PT1513525E (enExample)
RU (1) RU2324484C2 (enExample)
SE (1) SE0201943D0 (enExample)
SI (1) SI1513525T1 (enExample)
UA (1) UA81627C2 (enExample)
WO (1) WO2004000316A1 (enExample)
ZA (1) ZA200409908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
NZ548693A (en) * 2004-02-18 2010-05-28 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2556268A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
PT2001849E (pt) * 2006-03-29 2015-02-05 Hoffmann La Roche Derivados de piridina e pirimidina como antagonistas de r2mglu
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
US8703809B2 (en) 2008-06-30 2014-04-22 Novartis Ag Combination products
CN102573842A (zh) 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
JP2013529622A (ja) 2010-06-24 2013-07-22 ノバルティス アーゲー １ｈ−キナゾリン−２，４−ジオンの使用
BR112013018726A2 (pt) 2011-01-27 2016-10-25 Novartis Ag uso de ativadores de alfa 7 do receptor nicotínico de acetilcolina
AU2011376333A1 (en) 2011-09-07 2014-03-13 Novartis Ag Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
JP2016508159A (ja) 2013-01-15 2016-03-17 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
CN105263492B (zh) 2013-01-15 2018-04-10 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
MX2022005312A (es) * 2019-11-05 2022-05-26 Claes Thulin 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1, 2,4- triazol-3-il]piridina para el uso en la prevencion y/o tratamiento de la fatiga nerviosa en un mamifero.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
US6117908A (en) * 1996-09-18 2000-09-12 Astra Aktiebolag Use of GABAB receptor agonists as reflux inhibitors
WO2001012627A1 (en) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2002028837A1 (en) * 2000-10-02 2002-04-11 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
JP2002515448A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 食道逆流病の処置法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117908A (en) * 1996-09-18 2000-09-12 Astra Aktiebolag Use of GABAB receptor agonists as reflux inhibitors
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
WO2001012627A1 (en) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2002028837A1 (en) * 2000-10-02 2002-04-11 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
реферат Entrez PubMed Walker К. et al. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology. 2001; 40(1):1-9 [on-line] PMID: 11077065 [найдено 08.02.2007]. КОН P.M. и др. Ранняя диагностика болезней обмена веществ. - М.: Медицина, 1986, с.206-210. *
Энциклопедия лекарств. - М.: РЛС, 2001, с.1288, 1289, 1296, 1297. *

Also Published As

Publication number Publication date
PL372186A1 (en) 2005-07-11
DE60320990D1 (de) 2008-06-26
NO20050154L (no) 2005-01-11
UA81627C2 (ru) 2008-01-25
PT1513525E (pt) 2008-06-24
AU2003241585A1 (en) 2004-01-06
DK1513525T3 (da) 2008-08-11
EP1513525B1 (en) 2008-05-14
HK1075833A1 (en) 2005-12-30
ES2304510T3 (es) 2008-10-16
WO2004000316A1 (en) 2003-12-31
MXPA04012659A (es) 2006-05-25
EP1513525A1 (en) 2005-03-16
JP2006507225A (ja) 2006-03-02
JP4683920B2 (ja) 2011-05-18
CA2489730A1 (en) 2003-12-31
ZA200409908B (en) 2006-08-30
CN1662235A (zh) 2005-08-31
ATE395059T1 (de) 2008-05-15
RU2005101411A (ru) 2005-07-10
SI1513525T1 (sl) 2008-08-31
IS7654A (is) 2005-01-19
CY1107954T1 (el) 2013-09-04
SE0201943D0 (sv) 2002-06-20
JP2011068669A (ja) 2011-04-07
CA2489730C (en) 2011-11-22
IL165138A0 (en) 2005-12-18
CN100430056C (zh) 2008-11-05
NZ536559A (en) 2007-08-31
BR0311759A (pt) 2005-03-08
AU2003241585B2 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
RU2324484C2 (ru) Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)
CN101151030A (zh) 用于治疗血栓的包括至少一种直接凝血酶抑制剂的组合物
JP4048024B2 (ja) 新規経口製剤
JPWO2013081154A1 (ja) キナーゼ阻害剤の副作用低減剤
KR20010041110A (ko) 트라마돌을 함유하는 약제학적 배합물
JP2025027020A (ja) 患者において血清リン酸塩を低下させるための組み合わせ
US20110319464A1 (en) Methods for treating benign prostatic hyperplasia
CN101198334A (zh) 前列腺素化合物和质子泵抑制剂用于治疗肠胃病的联合应用
JP2005511632A (ja) 胃食道逆流疾患の治療のための新しい使用
EP1872795A1 (en) Therapeutic agent for irritable bowel syndrome
JP2002523363A (ja) 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用
JPWO2006118212A1 (ja) 膵炎の予防および治療剤
CN101316586A (zh) 5-ht4激动剂用于治疗可以由质子泵抑制剂诱导的胃排空延迟的用途
EP4337205A1 (en) Dosing regimens
TW201206432A (en) Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof
AU2002328569B2 (en) Medicinal compositions containing angiotensin II receptor antagonist
US7964609B2 (en) Use of mGluR5 antagonists for the treatment of gerd
KR20050024351A (ko) Ｇｅｒｄ 치료용 ｍｇｌｕｒ５ 길항제의 용도
KR20150036115A (ko) 위식도 역류증에 대한 약제
US7842702B2 (en) Treatment for irritable bowel syndrome
TW202440089A (zh) 用於治療間質性肺病之lpa1拮抗劑
JP2000355551A (ja) 医薬組成物
JP2025542301A (ja) 間質性肺疾患を処置するためのｌｐａ１拮抗薬
HK1075833B (en) Use of mglur5 antagonists for the treatment of gerd
WO2005058361A1 (en) USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD

Legal Events

Date Code Title Description
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 14-2008

MM4A The patent is invalid due to non-payment of fees

Effective date: 20120620